SER120 nasal spray 750 ng/day — Competitive Intelligence Brief

SER120 nasal spray 750 ng/day (SER120 nasal spray 750 ng/day) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Serotonin receptor agonist. Area: Psychiatry.

phase 3 Serotonin receptor agonist 5-HT1A Psychiatry Small molecule

Target snapshot

SER120 nasal spray 750 ng/day (SER120 nasal spray 750 ng/day) — Serenity Pharmaceuticals, Inc.. SER120 is a serotonin receptor agonist.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SER120 nasal spray 750 ng/day TARGET	SER120 nasal spray 750 ng/day	Serenity Pharmaceuticals, Inc.	phase 3	Serotonin receptor agonist	5-HT1A
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Aripiprazole/Escitalopram combination	Aripiprazole/Escitalopram combination	Massachusetts General Hospital	marketed	Atypical antipsychotic and selective serotonin reuptake inhibitor combination	Dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor (partial agonist), serotonin transporter (SERT inhibitor)
Buspirone + PAP therapy	Buspirone + PAP therapy	VA Office of Research and Development	marketed	5-HT1A receptor agonist (buspirone component); mechanical airway support device (PAP component)	5-HT1A receptor (buspirone); physical airway obstruction (PAP)
Treatment (Viibryd)	Treatment (Viibryd)	Southern California Institute for Research and Education	marketed	Serotonin-norepinephrine reuptake inhibitor (SNRI) with 5-HT1A partial agonist activity	Serotonin transporter (SERT); 5-HT1A receptor (partial agonist)
Buspirone and Grapefruit Juice	Buspirone and Grapefruit Juice	North Dakota State University	marketed	Serotonin 5-HT1A receptor partial agonist (buspirone component)	5-HT1A receptor (buspirone); CYP3A4 enzyme (grapefruit juice inhibition)
Latuda©	Latuda©	University of North Carolina, Chapel Hill	marketed	Atypical antipsychotic	Dopamine D2 receptor, serotonin 5-HT7 receptor, serotonin 5-HT1A receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Serotonin receptor agonist class)

1. Addpharma Inc. · 1 drug in this class
2. Organon and Co · 1 drug in this class
3. Serenity Pharmaceuticals, Inc. · 1 drug in this class
4. University Hospital, Strasbourg, France · 1 drug in this class